Date and Time
Wednesday, May 2, 2018
6:30 PM – 9:00 PM

Sheraton Grand Los Angeles
711 South Hope Street
Los Angeles, CA 90017
Click Here for a map

Register online here

Program Agenda – TBA

Please note: Only representatives from supporting pharmaceutical companies are invited to register. If your company is interested in becoming a Lymphoma Rounds supporter please contact Piper Harmon, Exhibit opportunities are also available, however, space is limited.
2017–18 Los Angeles Lymphoma Rounds Series –
Wednesday, October 4, 2017
Tuesday, February 6, 2018
Wednesday, May 2, 2018

About the Program
The Lymphoma Research Foundation's Los Angeles Lymphoma Rounds program provides a forum for healthcare professionals to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients. Participants will network, share best practices and learn the latest information on new therapies and advances in the management of lymphoma through interactive case studies presented by lymphoma experts in the Los Angeles area.

At the conclusion of this educational activity, the participant should be better able to:

  • Summarize the latest developments in lymphoma diagnosis, treatment and management.
  • Apply best practices for treating lymphoma patients.
  • Inform patients about potential clinical trial opportunities.
  • Establish a network of health care professionals who work with lymphoma patients.

Additional Information
This program is free for healthcare professionals; however, pre-registration is required. Food and refreshments will be provided for all registered participants.

Los Angeles Lymphoma Rounds Steering Committee

Cedars-Sinai Medical Center
Yuliya Linhares, MD
City of Hope
Auayporn Nademanee, MD
Olive View-UCLA Medical Center
Jeffrey Miller, MD
University of California, Irvine
Deepa Jeyakumar, MD
Lauren Pinter-Brown, MD, FACP (chair)
University of California, Los Angeles
Herbert Eradat, MD, MS
University of Southern California
Ann Mohrbacher, MD



This activity is supported by educational grants from

AbbVie, Celgene, Genentech, Juno Therapeutics, Kite Pharma, Pharmacyclics LLC and Janssen Biotech, Inc., Seattle Genetics, Spectrum Pharmaceuticals, Teva Pharmaceuticals Industries, LTD and TG Therapeutics

Joint Providership Statement

This activity has been planned and implemented in accordance with the Accreditation Requirements and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and the Lymphoma Research Foundation.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Statement

The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit (s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.